When Does U.S. Patent No. 9,035,074 for Abrocitinib Expire?
U.S. Patent No. 9,035,074, covering the drug abrocitinib, is currently set to expire on March 27, 2031 [1].
What is Abrocitinib?
Abrocitinib is a medication used to treat moderate to severe atopic dermatitis in adults and adolescents 12 years of age and older [2]. It belongs to a class of drugs called Janus kinase (JAK) inhibitors [3].
How Does Abrocitinib Work?
Abrocitinib selectively inhibits JAK1, an enzyme involved in the signaling pathways of cytokines that contribute to inflammation and immune responses [2][3]. By blocking JAK1, abrocitinib helps to reduce the itching and skin lesions associated with atopic dermatitis [2].
Who Makes Abrocitinib?
Abrocitinib is developed and marketed by Pfizer Inc. under the brand name CIBINQO [2].
What Are the Risks Associated with Abrocitinib?
Like other JAK inhibitors, abrocitinib carries warnings regarding serious infections, mortality, major cardiovascular events, thrombosis, and malignancy [2]. Patients should discuss these risks with their healthcare provider [2].
Are There Other Patents Covering Abrocitinib?
Drug patents can be complex, and there may be multiple patents covering different aspects of a drug, such as its formulation, method of use, or manufacturing process [4]. Patent information for abrocitinib can be found on resources like DrugPatentWatch.com [1][4].
Can Generic Versions of Abrocitinib Be Available Before Patent Expiry?
Generally, generic versions of a drug cannot be marketed in the U.S. until the relevant patents expire [4]. However, patent litigation can sometimes lead to earlier market entry for generics. Information on patent challenges and potential generic entry dates can be tracked through specialized patent databases [1][4].
---
Sources:
[1] DrugPatentWatch.com. (n.d.). Abrocitinib U.S. Patent Expiry Information. Retrieved from https://drugpatentwatch.com/
[2] U.S. Food & Drug Administration. (n.d.). FDA Approves CIBINQO (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis. Retrieved from https://www.fda.gov/
[3] Pfizer Inc. (n.d.). CIBINQO (abrocitinib) Prescribing Information.
[4] DrugPatentWatch.com. (n.d.). Understanding Drug Patents. Retrieved from https://drugpatentwatch.com/